Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merus
Biotech
FDA delays decision on Merus' first-in-class cancer drug
The agency has pushed back the decision date by three months to give its staff more time to assess recently submitted information.
Nick Paul Taylor
Nov 5, 2024 9:14am
Merus cancer bispecific lives up to investors' expectations
May 24, 2024 8:53am
Gilead bets $1.5B-plus on Merus' trispecifc T-cell engagers
Mar 6, 2024 10:02am
Merus shares dip as lung cancer data reveal 3 patient deaths
Dec 4, 2023 1:04pm
Merus' NRG1+ drug responses edge up in tough pancreatic cancer
Oct 23, 2023 7:30am
ASCO: Merus' gene-targeting cancer drug shrinks tumors
Jun 6, 2022 10:38am
